I don't think it is clinical data related, in this instance.
Done a bit of digging but need to verify some pieces of the puzzle.
Will send you a PM once i am sure of my dd.
( it's going to take me a while to check out a few things, limited time and swamped with my own work)
imo, this is not clinically related and believe BDTX is still on track with their excellent trials.
The replacement, Mark Valleca appears to be well experienced with medical development and the FDA.
This should bode well for BDTX as they move their clinical trials forward.
News 
Market Data 
Discover 
